Maria P Brizzi

Summary

Country: Italy

Publications

  1. doi Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature
    Maria Pia Brizzi
    Medical Oncology, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043, Orbassano, Torino, Italy
    BMC Cancer 15:914. 2015
  2. pmc Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study
    Alfredo Berruti
    Oncologia Medica, Dipartimento di Specialità Medico Chirurgiche, Scienze Radiologiche e Sanità Pubblica, Universita degli Studi di Brescia, Azienda Ospedaliera Spedali Civili Piazzale Spedali Civili 1, 25123 Brescia, Italy
    BMC Cancer 14:184. 2014
  3. pmc The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
    Stephen B Fox
    Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Breast Cancer Res 13:R16. 2011
  4. pmc Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network
    Maria P Brizzi
    Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Universita di Torino, Azienda Ospedaliera San Luigi, Regione Gonzole, 10, 10043 Orbassano TO, Italy
    BMC Cancer 9:388. 2009

Collaborators

Detail Information

Publications4

  1. doi Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature
    Maria Pia Brizzi
    Medical Oncology, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043, Orbassano, Torino, Italy
    BMC Cancer 15:914. 2015
    ..Paraneoplastic cerebellar degeneration (PCD) is the most common PNS, but it has never been reported in patients with pancreatic well-differentiated neuroendocrine tumours...
  2. pmc Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study
    Alfredo Berruti
    Oncologia Medica, Dipartimento di Specialità Medico Chirurgiche, Scienze Radiologiche e Sanità Pubblica, Universita degli Studi di Brescia, Azienda Ospedaliera Spedali Civili Piazzale Spedali Civili 1, 25123 Brescia, Italy
    BMC Cancer 14:184. 2014
    ....
  3. pmc The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
    Stephen B Fox
    Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Breast Cancer Res 13:R16. 2011
    ....
  4. pmc Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network
    Maria P Brizzi
    Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Universita di Torino, Azienda Ospedaliera San Luigi, Regione Gonzole, 10, 10043 Orbassano TO, Italy
    BMC Cancer 9:388. 2009
    ..A phase II study was designed to test the activity of protracted 5-fluorouracil (5FU) infusion plus long-acting release (LAR) octreotide in patients with neuroendocrine carcinoma...